Your browser doesn't support javascript.
loading
Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.
Vishwas, Sukriti; Kumar, Rajesh; Khursheed, Rubiya; Ramanunny, Arya Kadukkattil; Kumar, Rajan; Awasthi, Ankit; Corrie, Leander; Porwal, Omji; Arshad, Mohammed F; Alshammari, Mohammed Kanan; Alghitran, Abdulrahman A; Qumayri, Ashwaq N; Alkhaldi, Saif M; Alshammari, Abdulaziz Khalaf; Chellappan, Dinesh Kumar; Gupta, Gaurav; Collet, Trudi; Adams, Jon; Dua, Kamal; Gulati, Monica; Singh, Sachin Kumar.
Afiliación
  • Vishwas S; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Kumar R; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Khursheed R; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Ramanunny AK; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Kumar R; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Awasthi A; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Corrie L; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
  • Porwal O; Department of Pharmacognosy, Faculty of Pharmacy, Tishk International University, Erbil, 44001, KRG, Iraq.
  • Arshad MF; Department of Research and Scientific Communications, Isthmus Research and Publishing House, New Delhi, 110044, India.
  • Alshammari MK; Department of Pharmaceutical Care, Rafha Central Hospital, Rafha 91911, Saudi Arabia.
  • Alghitran AA; Department of Clinical Pharmacy, General Administration of Pharmaceutical Care, Ministry of Health, Riyadh 11176, Saudi Arabia.
  • Qumayri AN; Department of Clinical Pharmacy, General Administration of Pharmaceutical Care, Ministry of Health, Riyadh 11176, Saudi Arabia.
  • Alkhaldi SM; Department of Pharmaceutical Care, King Khalid Hospital in Majmaah, Riyadh Region 76312, Saudi Arabia.
  • Alshammari AK; College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
  • Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
  • Gupta G; School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India.
  • Collet T; Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
  • Adams J; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
  • Dua K; Innovative Medicines Group, Faculty of Health, Queensland University of Technology (QUT), Kelvin Grove, Brisbane, Queensland, 4059, Australia.
  • Gulati M; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
  • Singh SK; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Curr Neuropharmacol ; 21(7): 1558-1574, 2023.
Article en En | MEDLINE | ID: mdl-35950245
ABSTRACT
Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Nanopartículas Límite: Humans Idioma: En Revista: Curr Neuropharmacol Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Nanopartículas Límite: Humans Idioma: En Revista: Curr Neuropharmacol Año: 2023 Tipo del documento: Article País de afiliación: India